Glow-in-the-Dark dyes could catch esophageal cancer earlier

NCT ID NCT05745857

Recruiting now Diagnosis Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to find early signs of esophageal cancer in people with Barrett's esophagus. Participants will receive two fluorescent dyes (bevacizumab-800CW and cetuximab-800CW) either by mouth or directly on the esophagus before a standard endoscopy. The goal is to see if this method can spot abnormal tissue that regular endoscopy might miss. About 25 adults with Barrett's esophagus (with or without dysplasia) will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus esophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARRETT OESOPHAGITIS WITH DYSPLASIA BARRETT'S ESOPHAGUS WITHOUT DYSPLASIA ESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Medical Center Groningen
RECRUITING

Groningen, Provincie Groningen, 9713 GZ, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••